Trial reportEuropean journal of sport science2026
Gliclazide Enhances Exercise Performance and Recovery of Muscle Strength in Healthy Trained Individuals: A Randomized Controlled Trial.
Trial report in European journal of sport science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04443777 (Analysis of Ergogenic Potential and Risks Associated With Acute and Chronic Use of Sulphonylureas on Physical Exercise), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Ergogenic Potential and Risks Associated With Acute and Chronic Use of Sulphonylureas on Physical Exercise
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To examine the acute effect of gliclazide on exercise performance and recovery of muscle strength in healthy participants. We conducted a randomized, double-blind, placebo-controlled crossover clinical trial in 44 strength-trained men. They were allocated to gliclazide modified release (MR) (90 mg, 8h before exercise sessions) or placebo, undergo three consecutive sessions of strength exercise (four sets, 80% of one-repetition maximum [1-RM] of bench press and free squat exercise). We evaluated total volume-load (VL) (#repetitions x 80%1-RM), range of motion (ROM), insulin and glucose levels, creatine kinase MM (CK-MM), lactate dehydrogenase (LDH), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), hemodynamic parameters, perceived muscle soreness and recovery scores. Gliclazide enhanced strength exercise performance with improvements in total VL (bench press 23.3%, p < 0.001; squat 23.2%, p < 0.001), and improved muscle recovery 24-48h post-exercise: ROM (shoulder 1.1%, p < 0.001; knee 1.6%, p = 0.004), CK-MM (-13.2%, p < 0.001), LDH (-12.8%, p < 0.001), TNF-α (-17.4%, p < 0.001), IL-6 (-5.3%, p < 0.001), muscle soreness (-17.7%, p < 0.001) and recovery scores (32.5%, p = 0.001). However, hypoglycemia events were observed in 3 participants in the gliclazide group. In conclusion, Gliclazide MR 90 mg, 8h before strength exercise, produced ergogenic effects (exercise performance and muscle recovery), although hypoglycemia was observed in 7% of subjects. Registration: "www.clinicaltrials.gov", "NCT04443777" (Primary Completion: 01/08/2020; Study Completion: 31/10/2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.